|Dr. Jacinth K. Fairley||CEO, MD & Exec. Director||N/A||N/A||1963|
|Mr. Nigel J. Baade B.Com, CPA, Grad. Dip.||CFO & Company Sec.||N/A||N/A||N/A|
|Dr. A. Eglezos BSc(Hons),Ph.D., MBA||VP of Bus. Devel.||N/A||N/A||N/A|
|Dr. Jeremy R. Paull BSc (Hons), Ph.D.||VP of Devel. & Regulatory Affairs||N/A||N/A||N/A|
|Dr. David J. Owen BSc(Hons) Ph.D.||VP of Research||N/A||N/A||N/A|
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia and Canada. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel that is in Phase I clinical trial for breast, prostate, lung, and ovarian tumor. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharma Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.